OMRT-3. Longitudinal analysis of diffuse glioma reveals cell state dynamics at recurrence associated with changes in genetics and the microenvironment. (5th July 2021)

• Record Type: Journal Article
• Authors: Varn, Frederick; Johnson, Kevin; Barthel, Floris; Kim, Hoon; Wade, Taylor; Malta, Tathiane; Sabedot, Thais; Lodha, Disha; Ajaib, Shoaib; Ahmed, Nazia; Garofano, Luciano; D'Angelo, Fulvio; Stead, Lucy; Poisson, Laila; Noushmehr, Houtan; Iavarone, Antonio; Verhaak, Roel
• Is Part Of: Neuro-oncology advances. Volume 3(2021)Supplement 2
• Page Start: ii7
• Page End: ii8
• Publication Date: 2021-07-05
• Subjects: 616.99481
• DOI: 10.1093/noajnl/vdab070.029
• Languages: English
• ISSNs: 2632-2498

Abstract

Abstract: Diffuse glioma is an aggressive brain cancer that is characterized by a poor prognosis and a universal resistance to therapy. The evolutionary processes behind this resistance remain unclear. Previous studies by the Glioma Longitudinal Analysis (GLASS) Consortium have indicated that therapy-induced selective pressures shape the genetic evolution of glioma in a stochastic manner. However, single-cell studies have revealed that malignant glioma cells are highly plastic and transition their cell state in response to diverse challenges, including changes in the microenvironment and the administration of standard-of-care therapy. Interactions between these factors remain poorly understood, making it difficult to predict how a patient's tumor will evolve from diagnosis to recurrence. To interrogate the factors driving therapy resistance in diffuse glioma, we collected and analyzed RNA- and/or DNA-sequencing data from temporally separated tumor pairs of 292 adult patients with IDH-wild-type or IDH-mutant glioma. Recurrent tumors exhibited diverse changes that were attributable to changes in anatomic composition, somatic alterations, and microenvironment interactions. Hypermutation and acquired CDKN2A homozygous deletions associated with an increase in proliferating stem-like malignant cells at recurrence in both glioma subtypes, reflecting active tumor expansion. IDH-wild-type tumors were more invasive at recurrence, and their malignant cells exhibited increased expression of neuronal signaling programs that reflected a possible role for neuronal interactions in promoting glioma progression. Mesenchymal transition was associated with the presence of a specific myeloid cell state defined by unique ligand-receptor interactions with malignant cells, providing opportunities to target this transition through therapy. Collectively, our results uncover recurrence-associated changes in genetics and the microenvironment that can be targeted to shape disease progression following initial diagnosis.